Women’s Hormone Blood Tests: Estradiol, Progesterone, FSH, LH, Menopause, and PCOS

Women’s hormone blood tests measure ovarian, pituitary, adrenal, thyroid, pregnancy, blood-count, and metabolic markers. Depending on the question, testing may include an estradiol measurement, progesterone measurement, FSH, LH, AMH, prolactin, or focused androgen, thyroid, pregnancy, and metabolic tests. The right selection depends on symptoms, age, menstrual pattern, cycle day, medications, and reproductive goals.

No single hormone result diagnoses menopause, infertility, or polyendocrine metabolic ovarian syndrome (PMOS), the condition formerly called polycystic ovary syndrome (PCOS). AMH does not predict whether an individual will conceive naturally, and one FSH value does not prove menopause. Begin with a specific question, choose the smallest useful test set, and plan how an unexpected result will be confirmed or evaluated.

For broader context about specimens, screening, diagnostic support, and monitoring, use the complete guide to lab tests and blood work.

Part of the Ulta Lab Tests Knowledge Center

• The Complete Guide to Lab Tests and Blood Work explains specimens, panels, screening, diagnostic support, and monitoring.
• How to Read and Understand Your Lab Results explains reference intervals, decision limits, flags, units, and trends.
• Direct-Access Lab Testing: How It Works and What to Expect explains ordering, preparation, collection, results, and follow-up.
• Thyroid blood tests provide more detail about thyroid conditions that can resemble menstrual or menopause-related concerns.
• Fertility and preconception lab tests place ovarian reserve and ovulation testing within a broader fertility evaluation.
• Pregnancy blood tests and prenatal screening explain hCG, gestational timing, and pregnancy-specific testing.
• Metabolic health and GLP-1 monitoring provide context for glucose, lipids, weight-related risk, and longitudinal trends.

Key Facts About Women’s Hormone Blood Tests

Test or group	Common use	Timing or preparation	Major limitation
Estradiol, FSH, and LH	Selected menstrual, ovarian-pituitary, fertility, amenorrhea, or ovarian-insufficiency questions	Cycle day, life stage, pregnancy, birth control, and hormone therapy may matter.	One value is a snapshot and cannot diagnose menopause or fertility by itself.
Progesterone	Evidence of recent ovulation when correctly timed	Often about seven days before the expected next period, not automatically cycle day 21.	One result does not measure egg quality, pregnancy potential, or the whole luteal phase.
AMH	Ovarian reserve, anticipated response to stimulation, or selected adult PMOS/PCOS algorithms	Often collected on any cycle day; age, assay, ovarian surgery, body composition, and hormonal contraception can matter.	It does not predict natural conception, egg quality, exact egg count, or exact time to menopause.
Prolactin	Amenorrhea, galactorrhea, selected infertility questions, or pituitary symptoms	Stress, exercise, sleep, nipple stimulation, pregnancy, illness, and medicines may affect it.	A mild elevation may be temporary and often needs confirmation.
Testosterone with SHBG and DHEA-S	Hirsutism, acne with irregular cycles, virilization, or other androgen questions	Method quality, time of day, hormonal medication, and supplements matter.	One androgen result does not diagnose PMOS/PCOS or identify its source.
TSH, with free T4 when indicated	Thyroid disease as a possible cause of cycle, fertility, fatigue, or menopause-like symptoms	Biotin, illness, pregnancy, and medication timing can affect interpretation.	Normal thyroid results do not explain or exclude every cause of symptoms.
Quantitative hCG	Pregnancy assessment when a period is missed or pain, bleeding, or another question makes pregnancy relevant	Time since ovulation or conception matters; very early testing may be negative.	One value cannot locate a pregnancy or always establish viability.
75-g oral glucose tolerance testing, glucose, A1C, and lipids	Cardiometabolic risk assessment in PMOS/PCOS and other risk settings	Fasting or timed collection may apply; follow the exact order instructions.	These tests assess metabolic status, not the reproductive diagnosis by themselves.
CBC and ferritin	Anemia or iron depletion when bleeding is heavy or fatigue is present	Cycle timing is usually not central; fasting depends on accompanying tests.	They do not identify the structural cause of bleeding.

What Women’s Hormone Testing Can and Cannot Show

Women’s hormone testing is not one universal panel. It is a question-driven group of measurements that may assess communication among the hypothalamus, pituitary gland, ovaries, adrenal glands, thyroid, liver, blood cells, and metabolic systems. The same measurement can mean something different in an early-cycle fertility evaluation, prolonged amenorrhea, pregnancy, perimenopause, menopause, or medication monitoring.

Question	What testing may add	What testing cannot establish alone
Did ovulation likely occur?	A correctly timed progesterone result can support evidence of recent ovulation.	Egg quality, tubal patency, fertilization, implantation, or guaranteed conception.5
Is there an ovarian-pituitary pattern that needs follow-up?	FSH with estradiol, and sometimes LH, can add context for amenorrhea, ovarian insufficiency, or selected fertility questions.	A complete diagnosis from one collection.
Could prolactin be contributing to missed periods or breast discharge?	A persistent elevation can support medication review, thyroid or pregnancy assessment, and selected pituitary evaluation.	A pituitary diagnosis from one mildly high value.16
Are androgens elevated?	Total and free testosterone, SHBG, and DHEA-S can characterize a biochemical pattern.	PMOS/PCOS, an ovarian or adrenal source, or treatment from one value.9
Could thyroid disease be a look-alike?	TSH, often followed by free T4 when indicated, can identify a thyroid-axis pattern.	The cause of every fatigue, weight, cycle, fertility, or vasomotor symptom.
Is pregnancy possible?	Urine or serum hCG can support pregnancy assessment.	Pregnancy location or viability from one result.17
Is there PMOS/PCOS-related metabolic risk?	A 75-g oral glucose tolerance test, glucose, A1C, and lipids can assess glycemic and cardiovascular risk.	The reproductive syndrome from a metabolic result.1
Has heavy bleeding affected blood counts or iron stores?	A CBC and ferritin can identify anemia or depleted iron stores.	Fibroids, polyps, adenomyosis, endometrial disease, or another bleeding source.20

Blood tests cannot visualize the uterus, fallopian tubes, ovaries, or pituitary gland. They do not diagnose endometriosis, adenomyosis, fibroids, ovarian torsion, ectopic pregnancy, or osteoporosis. Imaging, examination, bone-density testing, semen analysis, genetic counseling, or specialist assessment may be the more appropriate next step.

Menstrual-Cycle Timing and Collection Context

This is an educational framework, not a diagnostic or treatment algorithm. Cycle day 1 is the first day of full menstrual flow, not light spotting. Protocols vary, and people with irregular or absent cycles may not have a reliable cycle day. Record the collection date, bleeding pattern, suspected ovulation date, medication or supplement use, and the timing of the last hormone dose.

Test or question	Common timing approach	Why timing matters	Key caution
FSH with estradiol in a fertility context	Often early follicular phase under a clinician’s or fertility program’s protocol.	Both vary across the cycle, and estradiol can affect how FSH is interpreted.	Do not interpret an early-cycle value without age, assay, medications, and the rest of the fertility evaluation.
Progesterone for ovulation evidence	Often about seven days before the expected next period.	Progesterone rises after ovulation and is secreted in pulses.	Day 21 fits only an approximately 28-day cycle; a mistimed low result can mislead.12
LH	Interpret serum LH with the cycle phase and clinical question.	A brief surge may occur before ovulation, and pituitary release is pulsatile.	A random serum value does not reliably confirm ovulation, and an LH-to-FSH ratio does not diagnose PMOS/PCOS.14
AMH	Often may be collected on any cycle day.	Cycle variation is generally smaller than for FSH or estradiol.	Age, assay, ovarian surgery, body composition, and current or recent hormonal contraception can influence the result.15
Prolactin	Any cycle day; a calm morning collection after rest may be preferred when confirming a mild elevation.	Stress, sleep, exercise, nipple stimulation, illness, pregnancy, and medicines can change the result.	Do not assume one mildly high value is persistent.
Total or free testosterone and SHBG	Consistent morning timing can improve comparability; document hormonal medication.	Concentrations and binding proteins vary with time, method, and medication.	Rapidly progressive virilization requires prompt professional evaluation, regardless of the preferred cycle day.
Typical perimenopause	No universal cycle day; routine hormone confirmation is often unnecessary in people age 45 or older with typical symptoms and cycle changes.	FSH and estradiol can fluctuate substantially during the transition.	Testing may still be appropriate for atypical age, pregnancy possibility, prolonged amenorrhea, or look-alikes.3
Quantitative hCG	Time since ovulation, conception, or a missed period matters more than a calendar cycle-day rule.	Very early hCG may be below detection.	Severe pain, bleeding, fainting, or weakness requires urgent evaluation rather than waiting for a preferred test date.

Symptom-to-Test Selection Pathway

1. Address urgency first. Severe pelvic pain, pregnancy-related pain or bleeding, fainting, rapidly worsening bleeding, acute neurological symptoms, or rapid virilization needs prompt professional evaluation.
2. Ask whether pregnancy is possible. For a missed period, bleeding, pelvic pain, or before selected procedures or medications, hCG may be the first laboratory question.
3. Define the dominant pattern. Is the concern absent or irregular periods, heavy bleeding, vasomotor symptoms, difficulty conceiving, androgen symptoms, breast discharge, or treatment monitoring?
4. Check common look-alikes. Depending on the pattern, thyroid testing, prolactin, a CBC, ferritin, medication review, or pregnancy testing may be more useful than a large sex-hormone panel.
5. Add reproductive hormones only when they answer the question. Use correctly timed progesterone for ovulation evidence; FSH with estradiol for selected ovarian-pituitary questions; AMH for ovarian-reserve or selected adult PMOS/PCOS algorithms; and focused androgen testing for androgen symptoms.
6. Separate reproductive evaluation from metabolic evaluation. Glucose status and lipids address long-term PMOS/PCOS risk even though they do not establish the reproductive diagnosis.
7. Plan confirmation before ordering. Decide whether an unexpected result would be repeated, confirmed with a more specific method, interpreted with imaging, or reviewed by a gynecologist, endocrinologist, or reproductive specialist.

Dominant question	Laboratory tests that may add information	Nonlaboratory evaluation often needed	Important limit or safety note
Missed or very irregular periods	hCG when pregnancy is possible; TSH; prolactin; FSH with estradiol; androgens when symptoms support them	History, medication and weight-change review, examination, and pelvic imaging when indicated	Pregnancy should remain near the front of the differential; amenorrhea has many causes.6
Heavy or prolonged bleeding	CBC, ferritin, hCG, TSH, and selected tests based on history	Pelvic examination, imaging, and sometimes endometrial evaluation	Very heavy bleeding with fainting, shortness of breath, chest pain, or severe weakness needs prompt care.20
Hot flashes, night sweats, or midlife cycle changes	Often no routine reproductive-hormone test for a typical presentation; targeted hCG, TSH, CBC, ferritin, or other tests for look-alikes	Clinical menopause assessment, bleeding review, preventive care, and treatment discussion	One FSH result does not diagnose menopause; bleeding after menopause needs evaluation.321
Difficulty conceiving	Correctly timed progesterone; AMH; selected FSH and estradiol; TSH or prolactin when indicated	Ovulation history, semen analysis, uterine and tubal assessment, ultrasound, and specialist evaluation	No single blood test is a fertility test.45
Acne, hirsutism, scalp hair loss, or irregular cycles	Total and free testosterone with SHBG, DHEA-S, and selected 17-hydroxyprogesterone; TSH and prolactin when appropriate	Examination, medication review, PMOS/PCOS criteria, and imaging when severe or atypical	Rapid virilization or markedly abnormal androgens requires prompt evaluation.9
Milky breast discharge, headaches, or visual symptoms	Prolactin, hCG, TSH, and medication review	Neurological and visual assessment; pituitary imaging when indicated	A severe new headache, vision loss, weakness, or confusion requires urgent care.
Known or suspected PMOS/PCOS	Focused reproductive and androgen tests plus glycemic and lipid assessment	Diagnostic criteria, blood pressure, sleep-apnea risk, reproductive goals, and long-term care	Routine insulin assays are not recommended as a diagnostic test for the syndrome.1

Testing-Tier Overview

These tiers describe how tests are commonly used; they are not a ranking of quality or importance. A larger panel is not automatically more accurate or more useful.

Common or First-Line Tests

• hCG when pregnancy is possible in amenorrhea, bleeding, pain, or before selected procedures or medications.
• TSH when thyroid dysfunction is a plausible cause of menstrual, fertility, fatigue, or menopause-like symptoms.
• Prolactin for amenorrhea, galactorrhea, selected infertility questions, or pituitary symptoms.
• A CBC and ferritin for heavy bleeding, fatigue, or suspected iron depletion.
• Total and free testosterone with SHBG for clinically significant hirsutism, acne with cycle disturbance, or other androgen symptoms.
• Glucose-status and lipid testing for PMOS/PCOS or another metabolic-risk question.

Risk-Based or Targeted Tests

• FSH with estradiol for selected amenorrhea, primary ovarian insufficiency, ovarian-pituitary, or fertility questions.
• Progesterone timed to the expected luteal phase when evidence of recent ovulation is needed.
• AMH for ovarian-reserve or ovarian-response questions and selected adult PMOS/PCOS algorithms.
• DHEA-S when adrenal androgen contribution is relevant.
• Estrone for selected postmenopausal, exogenous-estrogen, or specialist questions rather than routine screening.
• A 75-g oral glucose tolerance test when a more sensitive glycemic assessment is appropriate in PMOS/PCOS or pregnancy planning.¹

Monitoring Tests

• Known thyroid, prolactin, glucose, lipid, or ovarian conditions may require longitudinal testing under condition-specific guidance.
• Fertility-treatment protocols may use serial estradiol, progesterone, LH, hCG, or other markers under specialist direction.
• Hormone-therapy monitoring should answer a defined question about absorption, adherence, unexpected symptoms, bleeding, or treatment safety rather than pursue a universal “optimal” number.
• When possible, keep the method, timing, and preparation comparable so a trend is easier to interpret.

Specialist-Directed Tests

• 17-hydroxyprogesterone, androstenedione, stimulation or suppression procedures, and other adrenal testing for selected hyperandrogenic presentations.
• More sensitive steroid methods when concentrations are expected to be low or an immunoassay conflicts with the clinical pattern.
• Macroprolactin evaluation, dilution studies, or pituitary imaging for selected prolactin patterns.
• Genetic or autoimmune evaluation for selected primary ovarian insufficiency presentations.

Emerging or Insufficiently Validated Uses

• Broad salivary or urinary steroid panels used to diagnose a vague “hormone imbalance” or titrate menopausal therapy are not established replacements for clinical assessment and validated testing.
• Commercial “fertility age” scores derived from AMH or ovarian-reserve markers can overstate what is known about natural conception.
• Estrogen-metabolite ratios, “estrogen dominance” scores, and broad wellness algorithms often lack validated decision thresholds linked to better outcomes.

Generally Not Appropriate for Broad Routine Screening

• A random FSH measurement to screen an otherwise healthy midlife person for menopause.
• AMH to predict whether a person without a fertility indication can conceive naturally now or later.
• Serial estradiol, progesterone, or FSH measurements without a defined diagnostic or monitoring question.
• The LH-to-FSH ratio as a stand-alone PMOS/PCOS test.
• Routine fasting insulin as a diagnostic test for PMOS/PCOS.¹
• A broad hormone panel when urgent evaluation, pregnancy assessment, pelvic imaging, or examination is the more appropriate first step.

Detailed Women’s Hormone and Related Test Guide

Product names and links below were revalidated against current official Ulta Lab Tests signals on August 7, 2026. Product availability and instructions can change. Before ordering or publishing, confirm the visible product title, specimen, preparation, location availability, and current page in an authorized browser.

Ovarian, Menstrual-Cycle, Pituitary, and Pregnancy Tests

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
Estradiol Test Aliases: E2, 17-beta estradiol Use status: Common or first-line; monitoring when question-driven	Measures the principal circulating estrogen during reproductive years. It may support evaluation of menstrual irregularity, amenorrhea, ovarian-pituitary function, fertility, ovarian insufficiency, selected menopause questions, or hormone exposure.	Record cycle day and hormone-medication timing. Pregnancy, fertility medication, body composition, liver function, assay method, and biotin may affect interpretation. One value cannot establish menopause, fertility, symptom cause, or treatment need.11
Estrone, LC/MS/MS Test Alias: E1 Use status: Risk-based or targeted	Measures an estrogen that becomes relatively more prominent after menopause and may be used for selected estrogen-exposure, postmenopausal, or specialist endocrine questions.	Document menopause status and hormone therapy. Body composition, liver function, exogenous estrogen, and method can affect the result. It cannot establish “estrogen dominance,” cancer risk, or treatment need.
Progesterone Test Alias: P4 Use status: Risk-based or targeted	May support evidence of recent ovulation when correctly timed and can be used in specialist fertility or pregnancy-treatment protocols.	For ovulation evidence, collection is often about seven days before the expected next period. Pulsatile secretion, pregnancy, progestin exposure, fertility medication, and assay method matter. One value cannot assess egg quality or guarantee conception.12
FSH Test Full name: follicle-stimulating hormone Use status: Common or first-line for selected questions	Measures the pituitary signal that stimulates ovarian follicles. It may support evaluation of amenorrhea, primary ovarian insufficiency, ovarian-pituitary patterns, or selected fertility questions.	Cycle phase, pregnancy, age, illness, birth control, hormone therapy, estradiol, and assay method may affect it. One result cannot establish menopause, exact egg count, egg quality, or natural fertility.13
LH Test Full name: luteinizing hormone Use status: Risk-based or targeted	Measures a pituitary hormone involved in ovulation and ovarian steroid production. It may add context in selected amenorrhea, ovarian-pituitary, fertility, or PMOS/PCOS evaluations.	Record cycle day. Pulsatile release, cycle phase, menopause, birth control, fertility medication, and assay method matter. A random serum value cannot reliably confirm ovulation, and the LH-to-FSH ratio cannot establish PMOS/PCOS.14
AMH Test Female Full name: anti-Müllerian hormone Use status: Risk-based or specialist-directed	Measures a marker related to the pool of small ovarian follicles. It is mainly used for ovarian-reserve and anticipated ovarian-response questions and may contribute to selected adult PMOS/PCOS algorithms.	Age, assay, body composition, ovarian surgery, and current or recent combined hormonal contraception may influence it. AMH cannot determine natural fertility, egg quality, exact egg count, time to menopause, or PMOS/PCOS by itself.415
Prolactin Test Alias: PRL Use status: Common or first-line for selected symptoms	Measures a pituitary hormone involved in lactation and reproductive-axis suppression when persistently elevated. It may be used for amenorrhea, galactorrhea, selected infertility concerns, headache, or visual symptoms.	A calm collection after rest can improve confirmation. Stress, exercise, sleep, pregnancy, medicines, kidney function, thyroid status, and macroprolactin may affect it. One high value does not diagnose pituitary disease.16
Prolactin Total and Monomeric Test Use status: Specialist-directed or confirmatory	May help clarify whether macroprolactin contributes to a persistent or clinically discordant prolactin elevation.	Use for a defined confirmation question rather than broad screening. Results still require medication, thyroid, pregnancy, kidney, symptom, and pituitary context.
hCG Total Quantitative Test Full name: human chorionic gonadotropin Use status: Common or first-line when pregnancy is possible	Measures serum hCG when pregnancy assessment or a quantitative trend is relevant.	Very early testing may be negative. Pregnancy dating, recent pregnancy, fertility medication, and assay interference can affect interpretation. One value cannot locate a pregnancy or always establish viability.17

Androgen and Selected Rule-Out Tests

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
Total and Free Testosterone with SHBG Use status: Risk-based or targeted	Provides total testosterone, a free-testosterone assessment, and SHBG context for clinically significant hirsutism, acne with cycle disturbance, virilization, or other androgen questions.	Morning collection and a reliable low-concentration method improve interpretability. Birth control, hormone therapy, supplements, liver or thyroid disease, and SHBG changes matter. One value does not diagnose PMOS/PCOS.19
Sex Hormone-Binding Globulin (SHBG) Test Use status: Risk-based or targeted	Measures the binding protein that influences the free fraction of testosterone and estradiol. It can help explain why total testosterone and androgen symptoms do not appear to match.	Estrogen exposure, thyroid and liver status, body composition, insulin-related factors, pregnancy, and medicines may change SHBG. It is not a diagnosis by itself.
DHEA-S Test Full name: dehydroepiandrosterone sulfate Use status: Risk-based or targeted	Measures a predominantly adrenal androgen and may help assess adrenal contribution when androgen symptoms are present.	Age, supplements, medicines, adrenal conditions, illness, and method matter. A result cannot identify an adrenal lesion or diagnose PMOS/PCOS by itself.
17-Hydroxyprogesterone Test Alias: 17-OHP Use status: Specialist-directed or targeted	May be used in selected hyperandrogenic presentations to evaluate a possible adrenal steroid-pathway condition.	Time of day and cycle phase can matter, and a borderline result may lead to a specialist-directed stimulation procedure. It is not a routine PMOS/PCOS screen.
Androstenedione Test Use status: Specialist-directed or targeted	Measures an androgen precursor that may add information when a history or other results justify broader steroid evaluation.	Cycle phase, age, medications, adrenal or ovarian function, and method matter. It does not establish the cause of androgen symptoms by itself.

Thyroid Look-Alikes

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
TSH Test Full name: thyroid-stimulating hormone Use status: Common or first-line when indicated	Evaluates the pituitary signal to the thyroid and may help identify thyroid dysfunction as a contributor to irregular periods, fertility concerns, fatigue, palpitations, temperature intolerance, or menopause-like symptoms.	Illness, pregnancy, biotin, thyroid medication timing, and other medicines can affect it. TSH alone does not explain every symptom or identify every thyroid condition.
Free T4 Test Full name: free thyroxine Use status: Risk-based or targeted	May help interpret an abnormal or clinically discordant TSH result and assess circulating unbound thyroxine.	Pregnancy, illness, biotin, medicines, and assay method can affect interpretation. It does not identify autoimmune thyroid disease by itself.
Thyroid Peroxidase and Thyroglobulin Antibodies Test Use status: Risk-based or targeted	May support evaluation of autoimmune thyroid disease when thyroid results, symptoms, pregnancy context, or history justify knowing the likely cause.	Positive antibodies do not measure current thyroid function or prove that thyroid autoimmunity caused a reproductive symptom. Interpret with TSH, free T4, and clinical context.

Metabolic, Blood Count, and Iron-Storage Tests

Test and quick facts	What it shows and how it is used	Preparation, influences, and limitations
Glucose Test Use status: Common or first-line; monitoring	Measures glucose at the collection time. When fasting status is known, it can contribute to glycemic-risk assessment in PMOS/PCOS and other settings.	Meals, fasting quality, stress, sleep, illness, exercise, and medicines may change it. One value cannot establish insulin resistance or long-term glycemia.
A1c Test Alias: HbA1c Use status: Common or first-line; monitoring	Estimates average glycemic exposure over roughly the prior two to three months and can support screening or monitoring.	Red-cell turnover, anemia, blood loss, transfusion, hemoglobin variants, kidney disease, and pregnancy may distort it. It can be less sensitive than an oral glucose tolerance test in PMOS/PCOS.1
Glucose Tolerance Test, 2 Specimens, 75g Alias: 75-g OGTT Use status: Risk-based or targeted	Measures fasting and post-load glucose under a timed protocol. The international PMOS/PCOS guideline identifies the 75-g oral glucose tolerance test as the most accurate glycemic assessment in this population when feasible.	Requires protocol-specific fasting, glucose-drink completion, and timed specimens. Recent illness, altered diet, exercise, medicines, vomiting, and timing errors may affect the result.1
Lipid Panel Test Use status: Common or first-line; monitoring	Measures cholesterol and triglyceride patterns that contribute to cardiometabolic-risk assessment in PMOS/PCOS and other settings.	Fasting depends on the question and current instructions. Diet, alcohol, illness, pregnancy, thyroid status, medicines, and weight change can affect results. A lipid result does not diagnose cardiovascular disease by itself.
Insulin Test Use status: Risk-based or targeted	Measures circulating insulin at one time point and may answer selected endocrine or metabolic questions when interpreted with glucose and clinical context.	Often requires fasting under the exact order instructions. Routine insulin assays have limited clinical relevance and are not recommended to diagnose PMOS/PCOS.1
Complete Blood Count with Differential and Platelets Alias: CBC Use status: Common or first-line for selected symptoms	Measures red cells, hemoglobin, hematocrit, white cells, and platelets. It may identify anemia or other blood-count changes when bleeding is heavy or fatigue is present.	Fasting and cycle timing are usually unnecessary. Hydration, altitude, smoking, pregnancy, illness, and recent blood loss may affect results. A CBC cannot identify the source of bleeding.
Ferritin Test Use status: Risk-based or targeted	Measures an iron-storage protein and may support evaluation of depleted iron stores after heavy menstrual bleeding or in selected fatigue and anemia patterns.	Inflammation, infection, liver disease, supplements, and recent iron treatment can alter the result. Ferritin cannot identify the cause of bleeding or explain every cause of fatigue.

PMOS, Formerly PCOS: Reproductive and Metabolic Evaluation

In May 2026, the American Society for Reproductive Medicine endorsed polyendocrine metabolic ovarian syndrome (PMOS) as the new name for the condition formerly known as polycystic ovary syndrome (PCOS). During the terminology transition, this guide uses PMOS, formerly PCOS, so readers can recognize both terms.²

PMOS/PCOS is a clinical syndrome, not one laboratory result. In adults, the 2023 international evidence-based guideline generally uses two of three features after alternative causes are considered: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or AMH within an appropriate adult algorithm. When irregular cycles and hyperandrogenism are already present, ultrasound or AMH is not required merely to add another criterion. AMH should not be used as the only diagnostic test, and neither AMH nor ovarian ultrasound is recommended to diagnose adolescents.¹

Evaluation lane	Core question	Laboratory information that may help	What the lane cannot establish alone
Cycle and ovulation	Are cycles persistently irregular, absent, or suggestive of ovulatory dysfunction?	hCG when pregnancy is possible; TSH; prolactin; correctly timed progesterone when ovulation evidence is needed; selected FSH with estradiol	The syndrome from irregular cycles or one progesterone result
Androgen	Is there clinical or biochemical hyperandrogenism?	Reliable total and free testosterone assessment, SHBG, DHEA-S, and selected 17-hydroxyprogesterone	The ovarian or adrenal source, a tumor, or PMOS/PCOS from one value
Ovarian morphology	Is morphology information needed after considering cycle and androgen findings?	Serum AMH may be used in adults within a validated algorithm.	Diagnosis from AMH alone, an ultrasound description alone, or adolescent use
Alternative causes	Could pregnancy, thyroid, prolactin, adrenal, ovarian, pituitary, medication, or energy-balance factors explain the pattern?	hCG, TSH, prolactin, and symptom-directed steroid or pituitary tests	A diagnosis of exclusion without adequate history and examination
Glycemic risk	Is glucose regulation abnormal now, and what is the future diabetes risk?	A 75-g oral glucose tolerance test when feasible; fasting glucose and/or A1C when it is unavailable, with lower sensitivity recognized	The reproductive diagnosis or insulin resistance from one insulin value
Lipid and cardiovascular risk	Are cholesterol or triglyceride patterns adding long-term risk?	A lipid profile at diagnosis and follow-up based on the result and overall risk	Cardiovascular disease or a medication decision from the lipid result alone

For broader glucose, lipid, liver, kidney, and weight-related context, see metabolic health and GLP-1 monitoring.

Perimenopause, Menopause, and Primary Ovarian Insufficiency

Typical perimenopause is usually identified from age, menstrual changes, and symptoms rather than a single hormone result. NICE advises against routinely using AMH, inhibins, estradiol, antral follicle count, or ovarian volume to identify perimenopause or menopause in people age 45 or older. FSH is reserved for selected circumstances, such as possible early menopause, primary ovarian insufficiency, or an unclear presentation.³

Primary ovarian insufficiency (POI) is not the same as typical menopause. In a person younger than 40 with prolonged irregular or absent periods and compatible symptoms, current guidance uses a clinical pattern plus biochemical evaluation; AMH is not the primary diagnostic test and may be considered only when FSH results are inconclusive.⁷ Premature or early menopause also deserves professional evaluation because fertility, bone, cardiovascular, and treatment questions may differ from typical midlife menopause.²²

Scenario	Usual starting point	When laboratory testing may add information	What not to infer
Typical symptoms and cycle changes at age 45 or older	Age, menstrual history, vasomotor and genitourinary symptoms, pregnancy possibility, medicines, and clinical risk review	Targeted hCG, TSH, CBC, ferritin, prolactin, or other tests for look-alikes when history supports them	That one FSH or estradiol value confirms or excludes the transition
Symptoms before age 45	Clinical evaluation of cycle pattern, pregnancy possibility, medicines, family history, surgery, chemotherapy, autoimmune, genetic, and nutritional factors	FSH with estradiol and other targeted evaluation according to the suspected cause	That one value establishes early menopause or POI
Using hormonal contraception	Exact method, dose, schedule, bleeding pattern, and reason for testing	Only tests that answer a defined question while accounting for expected suppression or altered binding proteins	That suppressed endogenous hormones reflect untreated ovarian function
Using menopausal hormone therapy	Symptoms, side effects, bleeding pattern, blood pressure, treatment adherence, route, dose, and individual risks	Targeted laboratory testing when absorption, adherence, an unusual symptom, or another endocrine question justifies it	That a universal serum hormone target guarantees relief or safety10
Bleeding after menopause	Prompt gynecologic evaluation	Blood tests may assess anemia or other contributors but do not replace examination, imaging, or endometrial evaluation.	That a normal hormone result makes the bleeding safe to ignore21

Low-estrogen states can affect bone health, but a hormone measurement does not measure bone density. For bone, muscle, metabolic, and longitudinal context, use healthy aging and longevity blood tests.

Fertility, Ovulation, and Ovarian Reserve

Fertility is influenced by age, ovulation, egg and sperm factors, the uterus, fallopian tubes, timing, health conditions, medication, and chance. A blood test can answer a focused endocrine question, but it cannot reduce fertility to a single score. ASRM states that ovarian-reserve markers are better at predicting ovarian response to stimulation than natural conception, and age remains a stronger predictor of reproductive success.⁴

• Progesterone: A correctly timed value can support evidence that ovulation recently occurred. It does not measure egg quality or guarantee conception.
• AMH: Useful for ovarian-reserve and anticipated ovarian-response questions. It is not a consumer fertility forecast and should not be used to deny or delay a broader evaluation.
• FSH with estradiol: May add early-cycle ovarian-pituitary context when a fertility clinician has defined the purpose and timing.
• TSH and prolactin: Used when menstrual history, symptoms, prior results, galactorrhea, or another endocrine question supports them; prolactin is not a universal routine infertility screen.⁵
• Nonlaboratory evaluation: Semen analysis, uterine and tubal assessment, ultrasound, and reproductive history may be more informative than repeating a broad hormone panel.

See the complete guide to fertility and preconception lab tests for female and male factors, preconception assessment, and the limits of hormone-only testing.

Hormonal Contraception, HRT, Supplements, and Assay Interference

Do not stop a prescription simply to obtain an untreated-looking result. Instead, document the exact product, dose, route, schedule, last dose, and reason for testing. Combined hormonal contraception can suppress ovulation, raise SHBG, lower measurable free testosterone, and lower AMH or antral follicle count in some settings; interpretation should account for that context.⁸

Influence	Results it may affect	Responsible action
Combined hormonal contraception	Ovulation, FSH, LH, estradiol, progesterone, testosterone, SHBG, AMH, and bleeding pattern	Record the method and timing. Do not stop without prescriber guidance because pregnancy risk may return.
Menopausal hormone therapy	Estradiol, progesterone, FSH, SHBG, and endogenous ovarian patterns	Record route, dose, schedule, last dose, symptoms, and reason for testing. Do not adjust to a universal number.
Fertility medication	Estradiol, progesterone, FSH, LH, and hCG	Follow the specialist’s protocol because timing and treatment actions can be cycle specific.
Androgen or DHEA supplements	Testosterone, DHEA-S, SHBG, estradiol, and related steroid measurements	Disclose all prescription and nonprescription hormone products. Do not assume a high result reflects endogenous production.
Biotin	Some immunoassays, including selected thyroid, hormone, and cardiac assays	Tell the laboratory and healthcare professional the dose and last use, and follow test-specific instructions. Do not stop a medically indicated supplement without guidance.19
Acute illness, stress, strenuous exercise, poor sleep, or dehydration	Prolactin, glucose, lipids, blood counts, thyroid results, and some reproductive hormones	Record collection conditions and consider a standardized repeat only when it would change the next decision.

Individual Test Versus Panel

The best option is the one that matches the question. Panel names, components, specimens, preparation, availability, and pricing can change, so review the current product page rather than relying on a remembered component list.

Option	When it may help	Advantages	Limitations and questions to ask
Single test	One focused question or confirmation of a prior finding	Lower chance of unrelated findings and simpler timing	May be incomplete when interpretation requires a pattern. Ask what decision the result will change.
Paired or small targeted set	Examples include FSH with estradiol or total testosterone with SHBG and a validated free-testosterone assessment.	Provides related context without an unfocused broad panel	Still requires correct timing, method, and clinical information. Ask why each component is needed now.
Focused fertility or ovarian-reserve panel	Specialist planning, ovarian-response assessment, or a defined fertility workup	Convenient when every component has a role	Does not assess tubes, uterus, semen, egg quality, or guaranteed pregnancy.
Focused PMOS/PCOS panel	When symptoms and cycle history support a syndrome evaluation	Can organize reproductive, exclusion, and metabolic questions	No fixed panel replaces diagnostic criteria; ask which criterion or alternative cause each component addresses.
Perimenopause or hormone-therapy panel	Atypical presentation, selected baseline, or treatment-specific question	Can consolidate a documented monitoring plan	Typical perimenopause often does not need routine hormone confirmation, and untargeted testing can create incidental findings.
Broad “hormone balance” panel	Only when every component is justified by a defined question	One collection can gather multiple relevant measurements	Higher risk of incidental findings, false positives, anxiety, and unclear actionability. Ask whether the panel can be narrowed.

How to Understand Women’s Hormone Test Results

Start with the complete report: exact test name, result, unit, laboratory reference interval or decision limit, specimen, method, collection date and time, cycle day, pregnancy status, medications, supplements, and any laboratory comments. The guide to how to read and understand lab results explains flags, intervals, units, thresholds, and trends in more detail.

Term	Meaning	Why it matters in hormone testing
Reference interval	A range derived from a defined comparison population using a particular method	It may differ by laboratory, age, sex-related biology, cycle phase, pregnancy, or menopause status.
Diagnostic or decision threshold	A boundary used within a guideline or clinical pathway	It may require symptoms, repeat confirmation, or related findings and is not interchangeable with a report flag.
Treatment target	A goal selected for a specific condition or therapy	There is no universal “optimal hormone balance” target for every person.
Trend	Change across comparable measurements	Method, cycle timing, dose timing, illness, and preparation must be similar enough for the comparison to be meaningful.

A Fictional Qualitative Walkthrough

Consider a fictional patient, Maya, who has irregular cycles, gradual hirsutism, and no urgent symptoms. Her report contains a mildly elevated prolactin, an androgen pattern that may be abnormal for the performing laboratory, AMH above the laboratory’s age- and method-specific comparator, and triglycerides above the report interval. FSH and estradiol were collected early in a documented cycle.

Finding	What it may add	Responsible follow-up question
Mildly elevated prolactin	May be temporary or related to stress, medicines, pregnancy, thyroid status, macroprolactin, or pituitary factors	Were collection conditions controlled, and does the result need repeat or monomeric confirmation?
Abnormal androgen pattern	May support biochemical hyperandrogenism when a reliable method and clinical pattern agree	Does the method perform well at low female concentrations, and should the result be confirmed?
AMH above the method-specific comparator	May occur with a larger small-follicle pool and can contribute to an adult PMOS/PCOS algorithm	Is AMH needed, or do cycle dysfunction and hyperandrogenism already answer the diagnostic-criteria question?
Triglycerides above the report interval	Adds a metabolic-risk signal separate from the reproductive diagnosis	How does it fit with fasting status, blood pressure, glucose assessment, sleep, family history, and overall cardiovascular risk?

A responsible interpretation would not diagnose Maya from this report alone. The pattern could justify confirmation of prolactin and androgen findings, clinical evaluation for PMOS/PCOS and alternative causes, and a separate metabolic-risk assessment. It would not prove infertility, predict a future pregnancy, or determine hormone treatment.

When Repeat or Confirmatory Testing May Be Needed

Situation	Why confirmation may help	General next-step concept
Mildly elevated prolactin	Stress, exercise, sleep, medicines, pregnancy, hypothyroidism, and macroprolactin may affect it.	Repeat under controlled conditions and review medicines and clinical context before pituitary conclusions.
Unexpected testosterone elevation or a value that conflicts with symptoms	Low female concentrations challenge some immunoassays; supplements, contamination, and SHBG changes may mislead.	Consider confirmation with a reliable total-testosterone method and a validated free-testosterone approach.
One high FSH result in perimenopause or suspected POI	FSH fluctuates, and criteria depend on age, menstrual pattern, duration, and medication context.	Use current menopause or POI guidance and repeat when the pathway requires it.7
Negative hCG very early after possible conception	hCG may not yet be detectable.	Repeat based on timing and symptoms; urgent pain or bleeding requires clinical evaluation rather than routine serial self-testing.
Borderline or discordant thyroid results	Illness, medicine timing, biotin, pregnancy, pituitary disease, and assay interference may affect the pattern.	Repeat with appropriate preparation and add free T4 or specialist evaluation when indicated.
Any result near an important decision threshold	Analytical and biological variation can move a value across a boundary.	Confirm according to the relevant guideline rather than treating one flag as a diagnosis.

Repeat testing should have a purpose. Repeating every minor flag can add cost, anxiety, and incidental findings without improving a decision. When comparing trends, use the same laboratory and method when practical and keep collection conditions as consistent as possible.

When Professional or Urgent Care Is Needed

Seek urgent or emergency evaluation now when appropriate

• Possible pregnancy with severe or one-sided pelvic or abdominal pain, heavy bleeding, fainting, dizziness, shoulder pain, or weakness.¹⁸
• Bleeding that rapidly soaks pads or tampons, especially with fainting, shortness of breath, chest pain, severe weakness, or a racing heartbeat.
• Sudden severe pelvic pain, pain with fever or vomiting, or rapidly worsening abdominal symptoms.
• A new severe headache, vision loss or major visual change, weakness, numbness, confusion, or seizure.
• Rapid virilization, such as quickly developing voice deepening, clitoral enlargement, marked muscle change, or rapidly progressing coarse hair growth.
• Chest pain, sudden shortness of breath, coughing blood, one-sided leg swelling, or stroke-like symptoms while using hormone therapy or another medicine associated with clot risk.

Arrange prompt professional evaluation

• Bleeding after menopause, even if it is light or intermittent.²¹
• Periods that stop for several months without a known explanation, especially before the expected menopause age.
• Persistent galactorrhea, recurrent headaches, or visual symptoms.
• New or worsening hirsutism, acne, scalp hair loss, or abnormal androgen results.
• Heavy or prolonged periods, anemia symptoms, or repeated iron depletion.
• Difficulty conceiving, recurrent pregnancy loss, or fertility-preservation decisions.
• Unexpected or repeatedly abnormal hormone results, particularly while using hormonal medication.

Related Individual Tests and Health Guides

Use product links only after checking the exact current page. Product names, preparation, availability, and pricing may change. Testing should remain question-driven; a larger panel is not automatically more useful than an individual test.

Ovarian and Pituitary Tests

• estradiol testing for selected ovarian, menstrual, fertility, menopause, or hormone-exposure questions
• estrone testing for selected estrogen-exposure and postmenopausal questions
• progesterone testing for correctly timed evidence of recent ovulation
• FSH testing for selected ovarian-pituitary patterns
• LH testing for selected pituitary-ovarian questions
• AMH testing for ovarian reserve and selected adult PMOS/PCOS algorithms
• prolactin testing for amenorrhea, galactorrhea, and selected pituitary questions

Androgen, Thyroid, Pregnancy, Metabolic, and Bleeding-Related Tests

• a total and free testosterone assessment with SHBG
• DHEA-S testing for selected adrenal-androgen questions
• TSH testing for a possible thyroid look-alike
• quantitative hCG testing when pregnancy assessment is relevant
• a timed 75-g oral glucose tolerance test for selected glycemic-risk assessment
• A1C testing for longer-term glycemic exposure
• lipid testing for cholesterol and triglyceride patterns
• a complete blood count when heavy bleeding or anemia symptoms are present
• ferritin testing for selected iron-storage questions

Related Health Guides

• Thyroid Blood Tests: TSH, Free T4, Free T3, and Thyroid Antibodies
• Fertility and Preconception Lab Tests: Hormones, Ovulation, Ovarian Reserve, and Male Fertility
• Pregnancy Blood Tests and Prenatal Screening
• Metabolic Health Blood Tests: Weight Loss, Insulin Resistance, and GLP-1 Monitoring
• Healthy Aging and Longevity Blood Tests
• HRT and TRT Monitoring: Essential Blood Tests for Hormone Balance

How Ulta Lab Tests May Help

Where eligible and available, customers may browse laboratory tests online, review displayed pricing before ordering, use participating collection options, and access results through an online account. Availability and direct-access rules vary by location and product. Confirm the instructions, specimen, preparation, location availability, and current product details before completing an order.

Before ordering, define the question, record menstrual-cycle and medication timing, follow the exact preparation instructions, and decide who will interpret an unexpected result. Review how direct-access lab testing works from test selection through responsible follow-up.

Questions to Ask a Healthcare Professional

1. What specific clinical question are we trying to answer?
2. Could pregnancy, thyroid disease, anemia, medication, sleep problems, or another condition explain these symptoms?
3. Which measurements need a specific cycle day, time of day, fasting period, or medication timing?
4. How will birth control, menopausal hormone therapy, fertility medication, DHEA, or biotin affect interpretation?
5. Does the testosterone method perform well at low female concentrations?
6. Should progesterone be timed about seven days before my expected period rather than on a fixed cycle day?
7. What can AMH tell me about ovarian response, and what can it not tell me about natural fertility?
8. If PMOS/PCOS is being considered, which diagnostic features are present and which alternative causes need exclusion?
9. Do I need separate glucose, oral glucose tolerance, A1C, lipid, blood-pressure, or sleep-apnea assessment?
10. Would ultrasound, pelvic examination, bone-density testing, semen analysis, or another nonlaboratory evaluation answer the question better?
11. Which finding would need repeat confirmation, a different method, or specialist interpretation?
12. What symptoms should prompt urgent care?
13. How often, if at all, should testing be repeated, and what decision would a trend change?

Frequently Asked Questions

Which women’s hormone blood tests are usually considered first?

There is no universal first panel. Pregnancy testing, TSH, prolactin, a CBC with ferritin, androgen testing, FSH with estradiol, or correctly timed progesterone may be appropriate in different scenarios. A focused set is usually more useful than a broad “hormone balance” panel.

Can a blood test confirm perimenopause?

Usually not in one step. In people age 45 or older with typical symptoms and cycle changes, perimenopause is commonly assessed clinically, and routine hormone confirmation is often unnecessary. Targeted testing may help evaluate pregnancy, thyroid disease, anemia, prolactin disorders, POI, or other atypical features.³

Does one high FSH result mean menopause?

No. FSH can fluctuate, especially during perimenopause. Age, menstrual history, estradiol, hormonal medication, pregnancy possibility, and the reason for testing matter. A younger person with prolonged amenorrhea may need repeat testing and evaluation under current POI criteria.⁷

What is the best day to test FSH and estradiol?

For some fertility or ovarian-response questions, clinicians use the early follicular phase. Other questions, such as amenorrhea or suspected POI, may use different timing. The correct day depends on the purpose, not a universal calendar rule.

Should progesterone always be tested on cycle day 21?

No. Progesterone is commonly timed about seven days before the expected next period. Day 21 fits only an approximately 28-day cycle. Longer, shorter, or irregular cycles require different timing or specialist guidance.⁵

Can AMH tell me whether I can get pregnant naturally?

No. AMH estimates ovarian reserve and can help predict ovarian response to stimulation, but it is a poor independent predictor of natural conception or egg quality. Age and a complete fertility evaluation remain essential.⁴

Is there one blood test for PMOS or PCOS?

No. PMOS, formerly PCOS, is evaluated from a broader pattern involving ovulatory dysfunction, clinical or biochemical hyperandrogenism, and ovarian morphology after alternative causes are considered. AMH can be used in selected adults within an appropriate algorithm, but not alone and not for adolescent diagnosis.¹

Does the LH-to-FSH ratio diagnose PCOS?

No. The ratio varies and is not required for diagnosis. It should not replace menstrual history, androgen assessment, exclusion of alternative causes, and the adult diagnostic framework.

Which testosterone testing approach is preferred for women?

A reliable total-testosterone method, preferably LC-MS/MS when available for low female concentrations, is commonly used. Free testosterone should be measured or calculated with a validated approach using reliable total testosterone and SHBG. Direct analog free-testosterone immunoassays may be inaccurate at low concentrations.¹⁹

Can birth control change hormone results?

Yes. Combined hormonal contraception can suppress ovulation, raise SHBG, lower measurable free testosterone, and reduce AMH or antral follicle count in some settings. Record the exact method and do not stop contraception without prescriber guidance.⁸

Do estrogen levels need routine monitoring during menopausal hormone therapy?

Not for every person using standard menopausal hormone therapy. Targeted testing may help when absorption, adherence, unusual symptoms, bleeding, ovarian status, or another endocrine question is being evaluated. No universal serum estradiol target guarantees symptom relief or safety.¹⁰

Do I need to fast for a women’s hormone panel?

Many sex-hormone measurements do not require fasting, but glucose, insulin, an oral glucose tolerance test, triglyceride-focused lipid testing, or a combined order may. Follow the instructions for the exact order; when tests are grouped, the strictest requirement may apply.

What can cause a mildly high prolactin result?

Stress, exercise, sleep, nipple stimulation, pregnancy, medicines, hypothyroidism, kidney disease, macroprolactin, and pituitary conditions may affect prolactin. A mild isolated elevation often needs repeat confirmation under controlled conditions before conclusions are drawn.¹⁶

Can normal hormone results rule out a gynecologic condition?

No. Normal blood tests do not rule out endometriosis, adenomyosis, fibroids, ovarian cyst complications, uterine or tubal problems, pelvic-floor conditions, or every endocrine disorder. Persistent symptoms may still require examination, imaging, or specialist evaluation.

Conclusion

Women’s hormone blood tests can add useful information about menstrual changes, ovarian-pituitary function, ovulation, androgen symptoms, perimenopause, menopause, ovarian reserve, PMOS/PCOS, pregnancy, and related metabolic risk. The most informative testing plan starts with a specific question and records cycle, medication, fasting, specimen, and method context.

Testing cannot diagnose typical menopause from one FSH result, predict natural fertility from AMH, establish PMOS/PCOS from one hormone or ratio, identify structural pelvic disease, measure bone density, or choose hormone treatment by itself. Unexpected or discordant results may need standardized repeat testing, a more specific method, imaging, examination, or professional interpretation.

Primary References

1. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome, American Society for Reproductive Medicine and international guideline partners.
2. PCOS Is Now PMOS: Understanding the Name Change, American Society for Reproductive Medicine, May 27, 2026.
3. Menopause: Identification and Management — Recommendations, National Institute for Health and Care Excellence.
4. Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion, American Society for Reproductive Medicine, 2020.
5. Fertility Evaluation of Infertile Women: A Committee Opinion, American Society for Reproductive Medicine, 2021.
6. Current Evaluation of Amenorrhea: A Committee Opinion, American Society for Reproductive Medicine, 2024.
7. Evidence-Based Guideline: Premature Ovarian Insufficiency, American Society for Reproductive Medicine and guideline partners, 2025.
8. The Use of Hormonal Contraceptives in Fertility Treatments: A Committee Opinion, American Society for Reproductive Medicine, 2024.
9. Evaluation and Treatment of Hirsutism in Premenopausal Women, Endocrine Society Clinical Practice Guideline.
10. Hormone Therapy, The Menopause Society.
11. Estrogen Levels Test, MedlinePlus, U.S. National Library of Medicine.
12. MedlinePlus Guide to Progesterone Level Testing, U.S. National Library of Medicine.
13. Follicle-Stimulating Hormone Levels Test, MedlinePlus, U.S. National Library of Medicine.
14. Luteinizing Hormone Levels Test, MedlinePlus, U.S. National Library of Medicine.
15. Anti-Müllerian Hormone Test, MedlinePlus, U.S. National Library of Medicine.
16. Prolactin Levels, MedlinePlus, U.S. National Library of Medicine.
17. Pregnancy Test, MedlinePlus, U.S. National Library of Medicine.
18. Urgent Maternal Warning Signs, Centers for Disease Control and Prevention.
19. Biotin Interference with Laboratory Tests, U.S. Food and Drug Administration.
20. Period Problems, Office on Women’s Health, U.S. Department of Health and Human Services.
21. Menopause Basics, Office on Women’s Health, U.S. Department of Health and Human Services.
22. Premature Menopause, The Menopause Society.

Editorial Disclosure, Authorship, and Medical Note

Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.

Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026

Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.